Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.35 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.35 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26088923 | 0.88 | PRMT5 (0.40) | CRBNDDB1CHRM4EPHX2 | |
| SCHEMBL26435941 | 0.86 | ACHE (0.36) | CRBNDDB1FFAR4KDRCSNK1A1 | |
| SCHEMBL31417588 | 0.86 | CRBN (0.37) | CRBNDDB1FFAR4RIPK1RIPK3 | |
| SCHEMBL26087759 | 0.79 | CRBN (0.39) | CRBNDDB1ALDH1A1LMNATP53 | |
| SCHEMBL30349520 | 0.79 | CRBN (0.39) | CRBNDDB1ALDH1A1LMNATP53 | |
| SCHEMBL30349632 | 0.79 | DDB1 (0.36) | CRBNDDB1CHRM4POLBEPHX2 | |
| SCHEMBL26090625 | 0.79 | DDB1 (0.36) | CRBNDDB1CHRM4POLBEPHX2 | |
| SCHEMBL26089566 | 0.78 | LMNA (0.40) | CRBNDDB1KDM4EALDH1A1LMNA | |
| SCHEMBL30349451 | 0.77 | CACNA1H (0.36) | CRBNDDB1FFAR4POLB | |
| SCHEMBL26090376 | 0.77 | CACNA1H (0.36) | CRBNDDB1FFAR4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294495-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-05 | — | — | US | disclosed |
| WO-2023069731-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023069731-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294495-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CRBN, GSPT1, GSPT2 | CRBN 1/4885DDB1 157/4885FFAR4 4475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.